Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO) -- Ignore unavailable to you. Want to Upgrade?

To: AnnieO who wrote (127)	2/21/2000 3:55:00 PM
From: John Starks	Read Replies (1) \| Respond to of 286

i am a long time holder and have been obviously happy with the stock. i haven't contributed to the thread for awhile. the litigation has been a concern of mine as well but ceo lou gruber is a former patent attorney and i am pretty confident in their position, ie, their sbh technology appears to me (albeit i am a mol bio researcher, not a patent attorney!) to be distinct from arrays generally which is the affx holding. i am more concerned with the company's apparent goal of positioning itself as a pharma firm rather than a genomics company...three pre-clinical products will not sustain 1/10th its current value. wall street insists on lumping it with genomics stocks which accounts for the crazy run up obviously. lets hope the street continues to ignore the company's misguided attempt to redirect investor perception. i welcome any thoughts on the matter. John

To: AnnieO who wrote (127)	2/22/2000 9:37:00 AM
From: Richaaard	Read Replies (1) \| Respond to of 286

Annie, If you're going to espouse a short approach at least do some research on the company. The initial lawsuit was filed by HYSQ against AFFX. The case won't go on for years because a trial date is already set for this fall. Also, the CEO of HYSQ is a patent attorney who knows full well what he's up against. As for the costs to bring suit the shareholders know full well that attorney/lawsuit costs can be significant. As a shareholder I love it, the "payoff" from AFFX could be great.